(Q54679503)

2 June 2018

title

Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. (English)

1 reference

2 June 2018

author name string

C Alejandro Arce-Salinas

series ordinal

1

1 reference

2 June 2018

Felipe Rodríguez-García

series ordinal

2

1 reference

2 June 2018

J Iván Gómez-Vargas

series ordinal

3

1 reference

2 June 2018

publication date

22 January 2011

1 reference

2 June 2018

Rheumatology International

published in

1 reference

2 June 2018

volume

32

1 reference

2 June 2018

issue

5

1 reference

2 June 2018

page(s)

1245-1249

1 reference

2 June 2018

SLE patients with renal damage incur higher health care costs

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

New therapies for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

B cells as therapeutic targets for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Rituximab: a promising therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Factors associated with poor outcomes in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Treatment of severe proliferative lupus nephritis: the current state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1755-0

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

21 January 2018

1 reference

12 December 2020

Outcome criteria for lupus nephritis trials: a critical overview

1 reference

12 December 2020

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

1 reference

12 December 2020

Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement

1 reference

12 December 2020

Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices

1 reference

12 December 2020

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus

1 reference

12 December 2020

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

12 December 2020

Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis.

1 reference

12 December 2020

Rituximab-induced long-term remission of membranous lupus nephritis

1 reference

12 December 2020

A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease.

1 reference

12 December 2020

10.1007/S00296-010-1755-0

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018